



**The Green Organic Dutchman Holdings Ltd.**

**Management's Discussion and Analysis**

**For the three and nine months ended September 30, 2022 and  
September 30, 2021**

## MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis ("MD&A") reports on the interim condensed consolidated financial condition and operating results of The Green Organic Dutchman Holdings Ltd. (the "Company") for the three and nine months ended September 30, 2022 and 2021. The MD&A should be read in conjunction with the Company's interim condensed consolidated financial statements for the three and nine months ended September 30, 2022 and September 30, 2021 (the "Interim Condensed Consolidated Financial Statements") which were prepared in accordance with International Accounting Standards ("IAS") 34, International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). This MD&A provides information on the operating activities, performance and financial position of the Company and is intended to assist in understanding the Company's business and key factors underlying its financial results.

Additional information relating to the Company, including the Company's most recent annual information form for the year ended December 31, 2021 (the "Annual Information Form"), can be found on the Company's website at [www.tgod.ca](http://www.tgod.ca) or at the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com).

### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This MD&A may contain "forward-looking information" within the meaning of Canadian securities legislation ("forward-looking statements"). These forward-looking statements are made as of the date of this MD&A and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities laws. Forward-looking statements relate to future events or future performance and reflect Company management's expectations or beliefs regarding future events.

In some cases, these forward-looking statements can be identified by words or phrases such as "may", "might", "will", "should", "could", "expect", "anticipate", "estimate", "intend", "plan", "indicate", "seek", "believe", "predict" or "likely", or the negative of these terms, or other similar expressions intended to identify forward-looking statements. The Company has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes might affect its financial condition, results of operations, business strategy and financial needs. Some examples of forward-looking statements include but are not limited to the expected costs, production capacity, receipt of licences, etc.

#### *Assumptions*

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate and are subject to risks and uncertainties. In making the forward-looking statements included in this MD&A, the Company has made various material assumptions, including but not limited to:

- (i) the Company's ability to continue as a going concern and successfully execute its plans and intentions, including but not limited to the generation of revenues, positive operating cash flows from the sale of its products;
- (ii) the continued compliance of current financing arrangements and availability of additional financing at reasonable terms;
- (iii) the implications of the acquisition of the BZAM Acquisition (as defined below) to the Company's business;
- (iv) the ability of the Company to enter into the U.S. market;
- (v) continuing to obtain necessary regulatory approvals or renewals, including renewal of the Company's licenses granted by Health Canada;
- (vi) general business and economic conditions, particularly in the Canadian medicinal and adult-use cannabis markets;
- (vii) regulation of the markets in which the Company operates;
- (viii) the Company's ability to attract and retain skilled staff;
- (ix) market competition, including the products and technology offered by the Company's competitors;
- (x) maintenance of our strong ongoing relationships with our suppliers, service providers and other third parties; and
- (xi) the duration of COVID-19 and the extent of its economic and social impact.

Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There is no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We do not undertake to update or revise any forward-looking statements, except as, and to the extent required by, applicable securities laws in Canada. The Company's forward-looking statements are based on the reasonable beliefs, expectations, and opinions of management as of November 23, 2022, the date of this MD&A.

## BUSINESS OVERVIEW

The Company was incorporated under the Canada Business Corporations Act on November 16, 2016. The Company's registered and head office is located at 6205 Airport Rd., Building A – Suite 200, Mississauga, Ontario L4V 1E3. The Company's common shares (the "Common Shares") trade on the Canadian Securities Exchange ("CSE") under the symbol "TGOD" and on the OTCQX under the symbol "TGODF". The Company also had four classes of warrants listed on the CSE under the symbols "TGOD.WS", "TGOD.WR", "TGOD.WA" and "TGOD.WB".

The Company's wholly-owned Canadian subsidiaries, The Green Organic Dutchman Ltd. ("TGOD") and Galaxie Brands Corporation ("Galaxie") are licensed producers under the Cannabis Act (Canada) (the "Cannabis Act") and hold licences to produce cannabis plants, cannabis plant seeds, dried cannabis, fresh cannabis, cannabis oils, cannabis topicals, cannabis extracts and edible cannabis and sell such cannabis products within Canada to provincially authorized retailers or distributors and federally licensed entities. The Company owns cannabis cultivation facilities near Hamilton, Ontario (the "Hamilton Facility") and also has an operating licence in Puslinch, Ontario (the "Puslinch Facility") and a presence in Valleyfield, Québec (the "Quebec Facility").

In addition to its Canadian operations, the Company, through its subsidiaries and strategic investments, is pursuing an international growth strategy, and has established strategic partnerships for the distribution of cannabis derived medical products primarily focused in Germany.

The outbreak of the novel strain of the coronavirus, SARS-COV-2 ("COVID-19"), and its eventual declaration as a pandemic by the World Health Organization ("WHO") on March 11, 2020 resulted in governments worldwide enacting emergency measures to combat the spread of the virus. The Company continues to implement and evaluate actions to strengthen its financial position and support the continuity of its business and operations in response to the COVID-19 pandemic. The impact of the COVID-19 pandemic and geopolitical conflicts, including the recent war in Ukraine, have created much uncertainty in the global marketplace. The Company is closely monitoring the ongoing impact of such events on all aspects of its business, including how it will impact its services, customers, employees, vendors, and business partners now and in the future. While the COVID-19 pandemic and recent geopolitical conflicts did not materially adversely affect the Company's financial results and business operations in the nine months ended September 30, 2022, the Company is unable to predict the impact that these events will have on its future financial position and operating results due to numerous uncertainties.

Since inception, the Company has incurred recurring operating losses, having invested significantly in its cultivation facilities, research and development activities, selling, marketing, and general and administrative expenses. The Company has primarily financed its operations through equity and debt financings. The Company expects to continue to incur losses from operations in the short term and will require additional capital and increased revenues through the sale of its cannabis products to fulfill its financial obligations. Please refer to the section on "Liquidity and Capital Resources" below.

## KEY HIGHLIGHTS AND OUTLOOK

- Achieved quarterly gross revenues of \$13.82 million for the three months ended September 30, 2022 ("Q3 2022"), a 42% increase from the three months ended September 30, 2021 ("Q3 2021");
- Achieved quarterly net revenues of \$9.92 million, a 36% increase from Q3 2021;
- Successfully achieved a decrease in quarterly general and administrative expenses of \$2.2 million, a 34% decrease from Q3 2021 and a \$0.7 million or 14% decrease compared to Q2 2022;
- Net revenue for the nine months ended September 30, 2022 has increased by \$11.3 million (55%) compared to the same period in the prior year;
- As per Statistics Canada, Canada wide cannabis revenues have increased by 20% from January to August 2022 compared to the same period last year. The Company's net revenues have grown by 55% for the nine months to September 30, 2022 indicating a higher than market growth;
- Gross Profit for the nine months ended September 30, 2022 has increased by \$7 million (103%) compared to the same period in the prior year;
- In September 2022, the Company completed the sale HemPoland S.p.a. Z.o.o. ("HemPoland") for gross proceeds of \$6.8 million; and
- Subsequent to the quarter-end, completed the acquisition of BZAM Holdings Inc. ("BZAM"), approximately doubling the Company's revenue and asset base.

## BUSINESS OBJECTIVES AND RECENT DEVELOPMENTS

The Company’s goal is to build a sustainable global cannabis company that is trusted to improve the lives of its customers, employees, communities, and investors, with a focus on delivering a diverse range of premium and organic cannabis products.

The Company grows its organic cannabis in organic living soil, free from synthetic pesticides, herbicides and fertilizers. The Company has received third party organic certification from Pro-Cert, an internationally recognized leader in organic certification, for its Hamilton Facility. Organic certification requires the organization to maintain a strict compliance to organic standards and provides third party validation to consumers that the organization is following organic principles.

At its Hamilton Facility, the Company has made significant infrastructure investments in technology and automation for sanitation, growing environment and general cultivation. This includes additional HVAC systems, dehumidification systems, plant spacing strategies, soil beds, automated water systems, automated environmental control systems, waste handling and product tracking. The Company believes it is one of only a few licensed producers that provides premium organic cannabis and the only one capable of doing it at scale.

### ***Production Facilities and Licences***

The Company’s products are currently primarily cultivated and manufactured in the following licensed production facilities:

Facility	Location & Square Footage (Sq Ft)	Licence					Expiry of Current Licence Terms
		Cultivation	Processing	Sales to Other LPs	Sales to Provincial Boards	Research	
Hamilton Facility (TGOD)	Ancaster, ON 166,000 Sq Ft	✓	✓	✓	✓	✓	Cultivation/Processing/ Sale: July 20, 2027 Research Licence: February 12, 2025
Puslinch Facility (Galaxie)	Puslinch, ON 26,000 Sq Ft	✓	✓	✓	✓		Cultivation/Processing/ Sale: February 7, 2023
Quebec Facility (Medican Organic)	Valleyfield, QC 80,000 Sq Ft	✓	✓	✓			Pursuant to the Cannara Service Agreement (as defined below) <sup>(1)</sup>

**Note:**

<sup>(1)</sup> In connection with the sale of the Quebec Facility, the Company entered into an operating agreement with Cannara Biotech (Valleyfield) Inc. (“Cannara”), whereby the Company’s wholly-owned subsidiary Medican Organic Inc. (“Medican”), will operate out of approximately 80,000 square feet of cultivation and processing space in the Quebec Facility pursuant to a service agreement entered into between Cannara and Medican on September 26, 2021. The licence formerly held by Medican and tied to the Quebec Facility was transferred to Cannara on September 24, 2021. Medican Organic will provide services at the Quebec Facility to produce the Company’s premium certified organic cannabis. Additionally, the Company’s 2.0 products will continue to be manufactured at the Quebec Facility.

The Company anticipates that Health Canada will renew all licences at the end of their respective terms; however, the Company cannot provide assurances that the licences will be renewed or renewed on the same terms and conditions. See “Risk Factors”.

### ***Core Brands and Products***

In Canada, the Company has a growing product portfolio within multiple brands which cater to a diverse set of consumer segments.



**The Green Organic Dutchman** – The Green Organic Dutchman (“TGOD”) is the Company’s premium brand, focusing on certified organic cannabis flower and oil. The brand is distributed through the medical and recreational channels and is targeted at consumers that value superior product quality measures and sustainable cultivation and packaging. The brand has received notable recognition from industry authorities, like High Times, as one of the Top Cannabis Brands in North America, and the brand packaging routinely wins recognition as best-in-class.



**Highly Dutch** – Highly Dutch is the Company’s mainstream brand. Within this brand, the Company sells organic flower and concentrate products (hash). This brand is targeted more towards daily cannabis consumers enabling the trial and experience of the differentiation of organic cannabis.



**Cruzy** – Cruzy is a non-organic brand targeted towards legacy consumers, who often use cannabis as a part of their daily routine. Within Cruzy, the Company sells dried flower, extracts, and vapes.



**WYLD** – The Company, through a subsidiary joint venture, has an exclusive joint venture manufacturing and licensing agreement in Canada with the major U.S. edible brand WYLD to produce and distribute WYLD branded cannabis gummies.



**RIPPLE** – The Company has licensed the RIPPLE brand from Stillwater Brands in Colorado. The consistency, flexibility and portability of the products (RIPPLE dissolvable powders and RIPPLE QuickSticks) are desirable to a variety of consumers, especially those new to cannabis edibles.

***Innovation and New Products***

The Company has focused the product portfolio on categories which are optimized for innovation and profitability. Each brand has a product roadmap to take projects from innovation through R&D, consumer testing with TGOD’s research licence, and full market commercialization. In addition to having a rolling release of core product stock-keeping units (“SKUs”), like new dried flower strains, the Company is focused on providing new formats in other growing categories, like concentrates.

During Q3 2022, the TGOD brand continued to increase the distribution of several SKUs across Canada. As per previous quarters, sales focus and distribution growth was prioritized on the three dried flower SKUs of Organic Maple Kush, Organic Sugarbush and Organic Cherry Mints. Building on the pre-roll category, the brand also rolled out Organic Maple Kush 3 x 0.5g pre-rolls in Ontario during the quarter.

Highly Dutch Organic featured a notable quarter, including the launch of a new SKU, Amsterdam n’Rosin 0.5g vape. Additionally, the brand’s strong hash SKUs of Afghan Black and Marrakech Gold both expanded from 1g/unit to 2g/unit offerings. This size adjustment started in Alberta & Manitoba and will roll out to all provinces.

The Cruzy portfolio featured the newest SKUs for the organization. In Ontario, Puffing Season dried flower (3.5g), Ube Coconut vape (1g) and Rosin Charged Hash (1g) all launched in Q3. Additionally, the brand’s vape portfolio expanded into Alberta with three SKUs in 1g sizes.

***Canadian Distribution and Supply Agreements***

As of September 30, 2022, the Company held the following adult-use market distribution agreements:



**Société Québécoise Du Cannabis:** Purchase agreement to supply TGOD, Ripple, and Highly Dutch cannabis products.

**Ontario Cannabis Retail Corporation:** Purchase agreement to supply TGOD, Ripple, Highly Dutch, Cruzy and Wyld brand cannabis products.

**Alberta Gaming and Liquor-Commission:** Supply agreement to supply TGOD, Ripple, Highly Dutch, Cruzy and Wyld brand cannabis products.

**BC Liquor Distribution Branch:** Supply agreement to supply TGOD, Ripple, Highly Dutch, Cruzy and Wyld brand cannabis products.

**Manitoba Liquor & Lotteries Corporation:** Distribution agreement to supply TGOD, Ripple, Highly Dutch, Cruzy and Wyld brand cannabis products.

**Saskatchewan Liquor & Gaming Authority:** Authorization to supply TGOD, Ripple, Highly Dutch, Cruzy and Wyld brand cannabis products directly to private retail and wholesale markets.

**Nova Scotia Liquor Corporation:** Purchase agreement to supply TGOD, Ripple, Highly Dutch, Cruuzu and Wyld brand cannabis products.

**New Brunswick:** Purchase agreement to supply TGOD, Ripple, Highly Dutch, Cruuzu and Wyld brand cannabis products.

In addition to the adult-use distribution channels, the Company has a supply agreement with Shoppers Drug Mart Inc. making its premium and certified organic cannabis products available to medical patients.

### ***Sale of HemPoland Operations***

Since September 2021, the Company had been engaged with advisors for the sale of the Company's entity in Poland, HemPoland, which was deemed non-core to future operations and the Company's strategy. On September 6, 2022 the sale of HemPoland was completed with the purchaser paying a total of \$1.35 million in cash. A loan payable to HemPoland by the Company, of \$5.46 million was also forgiven. This brought the total proceeds to \$6.81 million.

The results of the HemPoland operations (the "HemPoland Operations") up to the date of sale have been included as discontinued operations in the Interim Condensed Consolidated Financial Statements and this MD&A.

### ***Revolver Loan Credit Facility***

The Company entered into the Revolver Loan on April 22, 2020, which was amended and restated on September 29, 2021, and further amended on November 29, 2021 (the "Amended and Restated Agreement"). The Revolver Loan had a credit limit of \$25 million, bears interest of 12%, with a maturity date of June 30, 2023. The Company must comply with certain financial covenants as set out in the Amended and Restated Agreement relating to the achievement of positive EBITDA (as defined in the Amended and Restated Agreement).

On March 10, 2022, the Company entered into a second amendment to the Amended and Restated Agreement (the "Second Amendment") whereby the Revolver Loan was amended to increase the overall Revolver Loan limit from \$25 million to \$30 million, allow certain eligible inventory to be included as collateral to the Revolver Loan, and relax certain covenants set forth in the Amended and Restated Agreement relating to the Revolver Loan. As consideration for the Second Amendment, the Company issued 500,000 Common Shares worth \$50 thousand to the lender.

On April 29, 2022, the Company entered into a third amendment to the Amended and Restated Agreement (the "Third Amendment"), whereby the Revolver Loan was amended to increase the overall Revolver Loan limit from \$30 million to \$34 million, increase the term portion of the Revolver Loan from \$20 million to \$24 million, amend the EBITDA financial covenant to take effect for the month ended June 30, 2022, remove the covenant requiring a \$6 million prepayment through funds raised by public issuance of equity securities in the Company, remove the covenant requiring a \$4 million prepayment through funds raised by the sale of HemPoland, and introduce certain prepayment fees in the combined amount of 2% of any prepayments, subject to the satisfaction of the various conditions set out therein.

The Revolver Loan is secured by a first lien over the Hamilton Facility and assets of the Company, including a lien over substantially all of the cannabis and cannabis derived inventories and Canadian trade receivables. As the accounts receivable balance eligible for collateral increases, additional credit is available to the Company.

As at September 30, 2022, the total principal balance outstanding related to the Revolver Loan was \$31.1 million.

In connection with the BZAM Transaction (as defined herein), the Company entered into a fourth amendment to the Amended and Restated Agreement (the "Fourth Amendment") to incorporate the assets of BZAM into the security collateral and, amongst other things: (i) remove the reduction of the limit to the revolving portion of the credit facility as a result of prepayment on the term portion of the credit facility; (ii) amend the EBITDA financial covenant to take effect on April 30, 2023; (iii) extend the maturity date of the credit facility to March 24, 2024; and (iv) introduce a 1.5% reduction of the interest rate upon achieving three consecutive months of positive earnings before depreciation and amortization, from TD Prime plus 8.05% to TD Prime plus 6.55%. All other terms of the Amended and Restated Agreement not specifically amended will remain the same as before. As consideration for the Fourth Amendment, the Company issued to the lender 7,000,000 warrants to purchase Common Shares at a price of \$0.095 per Common Share for a period of 60 months.

### ***Puslinch Facility***

On May 17, 2022, the Company closed an agreement of purchase and sale of its leasehold improvements of the Puslinch Facility (the "Puslinch Transaction") with the landlord for \$3 million (the "Consideration"). Of the Consideration, \$1.9 million was paid in cash, and \$1.1 million of the Consideration settled previous loans advanced to the Company by the landlord, including all accrued interest and transaction costs thereon. In connection with the Puslinch Transaction, the Company also agreed to an increase in rent of \$25 thousand a month for the remainder of the lease term on the Puslinch Facility of approximately 19 years.

### ***Other strategic initiatives including international expansion***

The Company continues to review other strategic initiatives to maximize shareholder value, including acquisitions in Canada. The Company also continues to pursue international and partnership growth opportunities in Germany.

Refer to the Company's summary of regulatory framework for the international markets in the "Regulatory Landscape" section below.

### ***Executive Leadership and Board Composition***

On February 1, 2022, the Company announced the appointment of Ms. Nichola Thompson as Chief Financial Officer ("CFO"), effective immediately. Concurrent with the appointment of Ms. Thompson as CFO, Mr. Sean Bovingdon resigned as interim CFO of the Company. On July 12, 2022, Ms. Thompson resigned from her position as CFO of the Company, effective August 4, 2022, to pursue unique opportunities outside of the cannabis industry. Mr. Bovingdon, Chief Executive Officer ("CEO") of the Company, was re-appointed Interim CFO, effective August 4, 2022.

On April 5, 2022, Mr. Nicholas Kirton retired as a member of the board of directors of the Company and the Chair of the audit committee of the Company (the "Audit Committee"). Mr. Chris Schnarr was appointed as the new Chair of the Audit Committee.

In connection with closing of the BZAM Transaction on November 3, 2022, Mr. Matt Milich was appointed as CEO, replacing Mr. Bovingdon, and Mr. Jordan Winnett was appointed Chief Commercial Officer. Mr. Bovingdon was appointed as CFO of the Company from Interim CFO. Also at this time, Dr. Caroline McCallum, Mr. Bovingdon and Mr. Adam Jaffe resigned from the Board of Directors, with two nominees of BZAM joining the Board, namely Mr. Keith Merker and Mr. Tony Moschella.

### ***Equity Issuances***

#### ***At-The-Market***

The Company issued Common Shares under its at-the-market ("ATM") prospectus supplement dated December 2, 2020 ("ATM Supplement"). The ATM Supplement permitted the Company to raise up to \$15 million from the issuance of Common Shares from time to time at a price equal to the then prevailing market price of the Common Shares as traded on the facilities of the CSE at the time of each direction. Under the ATM Supplement, during the nine months ended September 30, 2022, the Company issued 904,000 Common Shares for gross proceeds of \$105 thousand. The ATM Supplement expired on February 25, 2022.

	Common shares issued	Weighted average share price per share	Aggregate gross proceeds (\$ 000's)	Aggregate commissions paid (\$ 000's)	Aggregate net proceeds (\$ 000's)
February 2021	# 14,341,958	\$ 0.55	\$ 7,893	\$ 237	\$ 7,656
June 2021	1,073,000	0.36	389	12	377
August 2021	3,326,500	0.27	887	27	860
September 2021	1,350,500	0.25	336	10	326
December 2021	943,500	0.11	106	3	103
January 2022	398,000	0.11	44	1	43
February 2022	506,000	0.12	61	2	59
<b>Total</b>	<b># 21,939,458</b>	<b>\$ 0.44</b>	<b>\$ 9,716</b>	<b>\$ 292</b>	<b>\$ 9,424</b>

The ATM Supplement is a supplement to the Company's base shelf prospectus dated November 27, 2020 ("Base Shelf Prospectus"), which qualifies the distribution of up to \$50 million of securities of the Company to be raised through the issuance of various debt and equity securities of the Company over a period of up to 25 months from the date of the Base Shelf Prospectus. As at the date hereof, the Company is permitted to issue up to an additional \$27.63 million of debt and equity securities under the Base Shelf Prospectus.

### ***Convertible Security Issuances***

On April 7, 2022, the Company granted stock options to purchase an aggregate of up to 29,552,000 Common Shares to certain directors, officers, employees, and consultants of the Company, of which 19,950,000 stock options were granted to directors and executive officers, and 9,602,000 stock options were granted to employees and consultants. Each stock option is exercisable into one Common Share at an exercise price per Common Share equal to \$0.13. In addition, restricted share units representing the right to receive up to an aggregate of 350,000 Common Shares, subject to the satisfaction of certain vesting conditions, were also awarded to a consultant of the Company.

On May 27, 2022, the Company also granted stock options to purchase an aggregate of up to 89,000 Common Shares to certain employees. Each stock option is exercisable into one Common Share at an exercise price per Common Share equal to \$0.105.

On August 31, 2022, the Company also granted stock options to purchase an aggregate of up to 37,000 Common Shares to certain employees. Each stock option is exercisable into one Common Share at an exercise price per Common Share equal to \$0.085.

### ***Share Consolidation***

Subsequent to quarter-end, on November 8, 2022, the Company filed articles of amendment to effect a consolidation (the “Consolidation”) of all of the issued and outstanding Common Shares. Pursuant to the Consolidation, shareholders received one post-Consolidation Common Share for every ten pre-Consolidation Common Shares (the “Consolidation Ratio”). The Consolidation Ratio will also apply to the Common Share purchase warrants (the “Warrants”), which are currently exercisable on the basis of one Warrant for one Common Share. Accordingly, effective as of the Consolidation date, the holders of Warrants will be entitled to receive one post-Consolidation Common Share on the exercise of ten Warrants. The Consolidation also applied to the stock options and restricted share units outstanding, which were consolidated at the Consolidation Ratio with the exercise price being adjusted to reflect the Consolidation.

### ***COVID-19***

The Company continues to monitor and adapt to changing market conditions including but not limited to the ongoing impact of the COVID-19 pandemic. See “Risk Factors”. The Company has implemented several operational and financial responses to address the COVID-19 pandemic. Specifically, the Company has implemented precautionary measures at all Canadian locations to ensure the safety of the staff and product, including limiting visits to the sites to essential personnel only, ensuring proper protocols around sanitation, mask usage and physical distancing and ensuring potentially exposed employees remain in self-quarantine for the appropriate period.

### ***BZAM Transaction***

On October 18, 2022 the Company entered into a share exchange agreement with BZAM Holdings Inc., a corporation incorporated under the laws of the province of British Columbia (“BZAM”) and its sole shareholder BZAM International Ltd. (“BZAM Shareholder”), to purchase and acquire all of the issued and outstanding common shares of BZAM from the BZAM Shareholder (the “BZAM Transaction”) in exchange for 49.5% of the issued and outstanding shares (the “Combined Entity Shares”) of the combined entity formed upon closing of the BZAM Transaction (the “Combined Entity”), at a deemed price per Combined Entity Shares of \$0.0596 (the “Issue Price”). The BZAM Shareholder also has the ability to earn additional Combined Entity Shares valued up to \$33 million (the “Earnout Shares”), subject to achievement of certain milestones tied to annual net revenue targets and positive Adjusted EBITDA (a Non-GAAP Financial Measure, as defined below) targets for the 2023 calendar year (the “Milestones”).

On closing of the BZAM Transaction on November 3, 2022 (“Closing”), the Company paid a purchase price (the “Purchase Price”) as follows:

- a) A cash payment on Closing in the amount of \$100.00; and
- b) The issuance on Closing of an aggregate of 655,227,815 Combined Entity Shares, being 650,313,607 Combined Entity Shares issued to the BZAM Shareholder, and 4,914,208 Combined Entity Shares issued to Clarus Securities Inc. (“Clarus”) as payment by the BZAM Shareholder for certain finders fees owed by the BZAM Shareholder to Clarus in connection with the Transaction, which constitutes, on a pro forma basis immediately following Closing, 49.5% of the aggregate number of Combined Entity Shares issued and outstanding as of immediately following the Closing (the “Closing Shares”). For purposes of calculating the Closing Shares, the determination of the issued and outstanding Combined Entity Shares as of immediately following the Closing did not take into account (i) any securities issued by the Company that are convertible into, or exercisable for, Combined Entity Shares; or (ii) the 85,714,286 Common Shares (the “Milestone Escrow Shares”) held in escrow pursuant to a certain indemnity escrow agreement dated November 17, 2021, between the Company, Computershare Trust Company of Canada, and certain securityholders of the Company.

Following the release from escrow on December 31, 2022, of the Milestone Escrow Shares, the Company shall issue such number of Combined Entity Shares, equal to 49.5% of the aggregate number of Milestone Escrow Shares not returned to treasury of the Combined Entity, and issued to the escrow securityholders to the BZAM Shareholder, at the Issue Price.

The BZAM Transaction is expected to increase revenues and synergies which could result in a decrease in costs thereby increasing the overall profitability of the Combined Entity.



On October 3, 2022 and October 6, 2022 the Company received funds totalling \$2.2 million under a demand promissory note with a company controlled by the BZAM Shareholder. The promissory note bears interest at a rate of 12% per annum and demand can only occur after December 1, 2022. The promissory note is subordinated to the Amended and Restated Agreement.

## OVERALL PERFORMANCE

The focus of the Company's activity is the growth of commercial operations and the production and sale of its organically grown cannabis and non-organic consumer products in order to achieve positive Canadian operating cash flows. In addition to its Canadian operations, the Company, through its subsidiaries and strategic investments, is pursuing an international growth strategy primarily focused in Germany.

As described in the "Business Objectives and Recent Developments" section above, the Company continues to launch its newly commercialized products. In Canada, the Company continues to improve its harvest quantities and qualities in line with its plan. In addition, the Company continues to seek new product listings with its largest customers which are primarily provincial government cannabis boards. Listing its new products in each province will be a key catalyst to the future success of the Company. However, the Company believes that the ongoing changes to the regulatory environment have had and may continue to have certain adverse effects on distribution to the final end user customers, causing uncertainty with respect to:

- provincial cannabis boards are continually revising and updating their respective listing and purchasing procedures;
- the supply chain may be similarly affected as to whether its suppliers meet the local requirements to operate or not.

## SELECTED OPERATIONAL INFORMATION

### NON-GAAP PERFORMANCE MEASURES

This MD&A contains certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Readers are cautioned that these Non-GAAP Measures should not be construed as alternatives to net income determined in accordance with IFRS. For an explanation of these measures to related comparable financial information presented in the consolidated financial statements prepared in accordance with IFRS, refer to the discussion below. The Company believes that these Non-GAAP Measures are useful indicators of operating performance and are specifically used by management to assess the financial and operational performance of the Company. These Non-GAAP Measures include the following:

#### **Adjusted Earnings before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA")**

The Company has identified Adjusted EBITDA as a relevant industry performance indicator. Adjusted EBITDA is a non-IFRS financial measure used by management that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. Management defines Adjusted EBITDA as loss for the period, as reported, excluding foreign exchange gains and losses, finance costs, accretion expenses, finance income, revaluation loss (gain) of contingent consideration, loss (gain) on disposal of assets, impairment (reversal of impairment) charge for non-financial assets, loss on derecognition of investment in joint venture, debt modification, impairment loss on remeasurement of disposal group, gain on disposal of subsidiary, realized fair value adjustment on sale of inventories, unrealized gain on changes in fair value of biological assets, share based compensation, depreciation and amortization.

Management believes Adjusted EBITDA provides useful information as it is a commonly used measure in capital markets to approximate operating earnings. The Company provides the Non-GAAP Measure as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. The Non-GAAP Measure is also presented because management believes such measures provide information which is useful to shareholders and investors in understanding its performance and which may assist in the evaluation of the Company's business relative to that of its peers. Management believes the Non-GAAP Measure is a useful financial metric to assess the Company's operating performance on a cash basis before the impact of non-cash items, and on an adjusted basis as described above. However, such Non-GAAP Measure should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the most comparable Non-GAAP Measure.

A reconciliation of Adjusted EBITDA as compared to net loss from continuing operations, and a determination of specific components of Adjusted EBITDA, is presented below. **All dollar amounts in this section are presented in thousands of Canadian dollars unless specified otherwise.**

	For the three months ended		For the nine months ended	
	September 30, 2022	September 30, 2021	September 30, 2022	September 30, 2021
<b>Adjusted EBITDA (non-GAAP measure)</b>				
Net loss from continuing operations	\$ (6,862)	\$ (13,941)	\$ (26,696)	\$ (33,266)
Adjustments:				
Deferred income tax recovery	—	(628)	—	(628)
Foreign exchange loss (gain)	1,373	803	2,995	578
Finance costs	1,296	1,002	3,409	5,323
Accretion expense	384	295	1,186	5,148
Finance income	(6)	(8)	(13)	(55)
Revaluation gain of contingent consideration	(1,716)	—	(2,601)	(39)
Loss (gain) on disposal of assets	—	159	(8)	63
Impairment / (reversal of impairment) charge for non-financial assets	—	—	6,183	(21,811)
Loss on derecognition on investment in joint venture	—	—	—	761
Debt modification	—	(1,275)	48	(1,275)
Impairment loss on remeasurement of disposal group	—	4,442	2,489	4,442
Gain on disposal of subsidiary	(3,187)	—	(3,187)	—
Realized fair value adjustment on sale of inventories	8,597	1,765	14,877	5,626
Unrealized gain on changes in fair value of biological assets	(8,998)	(2,185)	(21,986)	(7,750)
Share based compensation	370	884	1,207	2,516
Depreciation and amortization	3,209	3,494	10,046	8,543
<b>Adjusted EBITDA (non-GAAP measure)</b>	<b>(5,540)</b>	<b>(5,193)</b>	<b>(12,051)</b>	<b>(31,824)</b>

**SUMMARY OF KEY QUARTERLY HIGHLIGHTS – Q3 2022 as compared to Q3 2021 and Q2 2022**

	Q3-2022	Q2-2022	Q1-2022	Q4-2021	Q3-2021	Q2-2021 *Restated	Q1-2021 *Restated	Q4-2020 *Restated
Revenue	\$ 13,819	15,841	14,353	12,372	9,745	10,400	6,668	8,549
Loss from operations	\$ (8,718)	(3,016)	(4,461)	(5,670)	(9,151)	(8,432)	(5,488)	(11,067)
Impairment loss on remeasurement of disposal group	\$ -	(2,489)	-	(676)	(4,442)	-	-	-
Gain on disposal of subsidiary	3,187	-	-	-	-	-	-	-
Loss on assets held for sale	\$ -	-	-	-	-	(17,688)	-	-
Reversal of impairment / (impairment) of Canadian CGU (as defined herein)	\$ -	-	(6,183)	-	-	-	21,811	-
Net income (loss) from continuing operations	\$ (6,862)	(6,622)	(13,212)	(6,278)	(13,941)	(32,181)	12,856	(14,620)
Loss from discontinued operations	\$ 21	(159)	(294)	(1,458)	(603)	(299)	(393)	(9,057)
Comprehensive income (loss)	\$ (8,851)	(7,161)	(14,015)	(8,097)	(14,061)	(32,525)	11,159	(23,874)
Net income (loss) per share (basic & diluted) - continuing operations	\$ (0.01)	(0.01)	(0.02)	(0.01)	(0.03)	(0.06)	0.03	(0.03)

\* Following the classification of the Company's HemPoland Operations as held for sale and discontinued operations, the comparatives prior to September 30, 2021, were restated to reflect only the continuing operations results historically.

## Revenues

	For the three months ended				Three months ended		
	September 30, 2022	September 30, 2021	Variance to Q3-2021 (\$)	Variance to Q3-2021 (%)	June 30, 2022	Variance to Q2-2022 (\$)	Variance to Q2-2022 (%)
Revenue from adult-use cannabis products	13,271	8,690	4,581	53%	15,154	(1,883)	(12%)
Revenue from medical cannabis products	543	552	(9)	(2%)	644	(101)	(16%)
Revenue from toll agreements	5	503	(498)	(99%)	43	(38)	(88%)
Total	13,819	9,745	4,074	42%	15,841	(2,022)	(13%)

Gross revenue recognized for the three months ended September 30, 2022, amounted to \$13,819, an increase of 42% compared to Q3 2021 (Q3 2021 - \$ 9,745). The increase is mainly due to the new launch of premium flower strains (Cherry Mints and Maple Kush), the new launch of Pre-rolls, and the Company's Highly Dutch Organic™ flower continuing to gain traction in 2022. With additional sales efforts undertaken to provide direct store support with budtender and consumer education, in addition to the new listings accepted in key markets throughout 2022, the Company achieved significant increased revenues in key markets.

Gross revenue decreased by 13% in comparison to Q2 2022 primarily due to decreased retail distribution as a result of cyber security issues that affected Ontario Cannabis Store in August, and the strike actions in British Columbia and Quebec that affected the distribution of cannabis in Q3 2022. In Q3 2022, some of the provinces were also drawing down on their inventory of new SKUs that launched in June 2022 of which they had front-loaded their orders.

## Gross profit

	Three months ended				Three months ended		
	September 30, 2022	September 30, 2021	Variance to Q3-2021 (\$)	Variance to Q3-2021 (%)	June 30, 2022	Variance to Q2-2022 (\$)	Variance to Q2-2022 (%)
<b>Net Revenue</b>	<b>9,922</b>	7,280	2,642	36%	11,627	(1,705)	(15%)
Cost of sales	9,326	5,154	4,172	81%	9,134	192	2%
Gross profit before changes in fair value of biological assets	596	2,126	(1,530)	(72%)	2,493	(1,897)	(76%)
<i>Gross profit % before changes in fair value of biological assets</i>	<i>6%</i>	<i>29%</i>			<i>21%</i>		
Realized fair value adjustment on sale of inventory	(8,597)	(1,765)	(6,832)	387%	(3,845)	(4,752)	124%
Unrealized gain on changes in fair value of biological assets	8,998	2,185	6,813	312%	8,683	315	4%
<b>Gross profit</b>	<b>997</b>	2,546	(1,549)	(61%)	7,331	(6,334)	(86%)
<i>Gross profit %</i>	<i>10%</i>	<i>35%</i>			<i>63%</i>		

The Company's gross profit before changes in fair value of biological assets ("**direct gross profit**") was \$596 for Q3 2022, representing 6% gross profit margin before changes in fair value of biological assets (Q3 2021 - \$ 2,126 representing 29% direct gross profit) reflecting a provision of \$1,690 that was made in Q3 2022 for potential obsolescence of inventory. Normalized direct gross profit without this provision would be \$2,286, or 23%.

The Company achieved an overall gross profit for Q3 2022 of \$997 (Q3 2021 – gross profit of \$ 2,546) which has decreased 61% from Q3 2021 mainly due to the inventory provision highlighted above as well as an additional provision of \$4,336 on the fair value portion of the inventory provided for above. In comparison to Q2 2022, the gross profit decreased 86%, by \$6,334 as a result of the aforementioned provisions. Without the additional provisions, the overall gross profit would have been \$7,023, or 71%.

### Sales and marketing expenses

	Three months ended				Three months ended		
	September 30, 2022	September 30, 2021	Variance to Q3-2021 (\$)	Variance to Q3-2021 (%)	June 30, 2022	Variance to Q2-2022 (\$)	Variance to Q2-2022 (%)
Personnel costs	358	357	1	0%	494	(136)	(28%)
Third party marketing expenses	749	555	194	35%	686	63	9%
Travel and promotion expenses	20	3	17	567%	14	6	43%
Sales agency costs	528	(83)	611	(736%)	417	111	27%
Other marketing expenses	169	58	111	191%	88	81	92%
	<b>1,824</b>	<b>890</b>	<b>934</b>	<b>105%</b>	<b>1,699</b>	<b>125</b>	<b>7%</b>

Sales and marketing expenses of \$1,824 for the three-months ended September 30, 2022 increased in comparison to expenses of \$890 for the same period in the prior year primarily due to additional sales efforts undertaken to provide direct store support as well as additional third-party marketing expenses commensurate with the increased revenue achieved. There were also additional costs that followed from the completion of the acquisition of all of the issued and outstanding shares of Galaxie (the “Galaxie Acquisition”), which increased the sales and marketing efforts in the current year.

In comparison to Q2 2022, sales and marketing expenses increased by \$125, primarily due to increased third party and sales agency costs.

### Research and development (“R&D”) expenses

	Three months ended				Three months ended		
	September 30, 2022	September 30, 2021	Variance to Q3-2021 (\$)	Variance to Q3-2021 (%)	June 30, 2022	Variance to Q2-2022 (\$)	Variance to Q2-2022 (%)
Personnel costs	49	52	(3)	(6%)	160	(111)	(69%)
Product development	34	-	34	n/a	1	33	3300%
Travel related expenses	-	8	(8)	(100%)	7	(7)	(100%)
Other research and development expenses	38	-	38	n/a	-	38	n/a
	<b>121</b>	<b>60</b>	<b>61</b>	<b>102%</b>	<b>168</b>	<b>(47)</b>	<b>(28%)</b>

R&D expenses of \$121 for the three-months ended September 30, 2022 increased by \$61 in comparison to the R&D expenses for Q3 2021. The Company incurred higher R&D costs due to the integration of Galaxie’s R&D personnel following completion of the Galaxie Acquisition.

In comparison to Q2 2022, R&D expenses decreased by \$47 due to reduced personnel costs as the Company rationalized some of its workforce in the Puslinch Facility.

### General and administrative (“G&A”) expenses

	Three months ended				Three months ended		
	September 30, 2022	September 30, 2021	Variance to Q3-2022 (\$)	Variance to Q3-2021 (%)	June 30, 2022	Variance to Q2-2022 (\$)	Variance to Q2-2022 (%)
Personnel costs	1,952	1,628	324	20%	2,349	(397)	(17%)
Office and other administrative expenses	261	3,537	(3,276)	(93%)	992	(731)	(74%)
Third party professional, consulting, legal fees	1,820	1,072	748	70%	1,465	355	24%
Computer and IT expenses	158	132	26	20%	94	64	68%
	<b>4,191</b>	<b>6,369</b>	<b>(2,178)</b>	<b>(34%)</b>	<b>4,900</b>	<b>(709)</b>	<b>(14%)</b>

G&A expenses of \$4,191 for the three months ended September 30, 2022, decreased by \$2,178 in comparison to expenses of \$6,369 for Q2 2021. The overall decrease primarily represents the Company's efforts to reduce all administration costs.

In comparison to Q2 2022, G&A expenses decreased by \$709 which is primarily a result of the Company's efforts to decrease costs including the reduction of overhead personnel.

### ***Share based compensation expenses***

The Company recognized a share based compensation expense of \$370 for the three months ended September 30, 2022, compared to \$884 for Q3 2021. The decrease is primarily due to a reduction in the value of stock options granted in Q3 2022 as well as stock options cancelled due to forfeiture and expiry. Share based compensation was valued using the Black-Scholes valuation model and represents a non-cash expense.

In comparison to Q2 2022, share based compensation expense increased by \$100 as a result of new options issued as well as less options cancelled due to forfeiture and expiry.

### ***Depreciation and amortization***

The Company recognized depreciation and amortization expense of \$3,209 for the three months ended September 30, 2022, compared to \$3,494 for the same period in the prior year despite the increase in the Company's asset base from the Galaxie acquisition which was offset by the impairment and subsequent sale and lease back of the building leasehold improvements at the Puslinch Facility (acquired in the Galaxie acquisition) in May 2022 as well as normal depreciation based on the reducing balance method. Additionally, depreciation decreased slightly by \$101 in Q3 2022 as compared to Q2 2022, due to normal depreciation based on the reducing balance method.

### ***Loss from operations***

Loss from operations was \$8,718 for the three months ended September 30, 2022, compared to \$9,151 for Q3 2021, with the improvement primarily driven by the lower general and administrative expenses.

In comparison to a loss from operations of \$3,016 in Q2 2022, the decline in Q3 2022 was mainly due to lower gross profit as discussed above, arising mainly due the provision made in Q3 of \$6,026, including fair value adjustment), for potential inventory obsolescence.

### ***Impairment loss***

During the three months ended September 30, 2022, the Company did not recognize an impairment loss (Q3 2021 – \$4,442).

### ***Net loss from continuing operations***

The Company's net loss from continuing operations for the three months ended September 30, 2022, was \$6,862 (Q3 2021 – net loss of \$13,941) which has decreased primarily due to the lower expenses, gain on the revaluation of the contingent shares from the Galaxie Acquisition of \$1,716 and a gain of \$3,187 from the sale of HemPoland.

### ***Comprehensive loss***

The Company's comprehensive loss for the three months ended September 30, 2022, was \$8,851 (Q2 2021 - comprehensive loss of \$32,525) and is comprised primarily of the net loss from continuing operations discussed above.

In comparison to Q2 2022, the Company's comprehensive loss in Q3 2022 increased by \$1,690 primarily due to the lower gross profit and the transfer to profit and loss of the foreign currency translation reserve gains relating to HemPoland on its sale.

## ***SUMMARY OF NINE MONTHS ENDED SEPTEMBER 30, 2022 ("YTD") RESULTS – YTD 2022 as compared to YTD 2021***

The table below summarizes selected information regarding the Company's loss from operations and other financial information for the periods presented in accordance with IFRS and on a consistent basis with the Interim Condensed Consolidated Financial statements and related notes:

	For the nine months ended	
	September 30, 2022	September 30, 2021
Revenue	\$ 44,013	\$ 26,813
Loss from operations	\$ (16,195)	\$ (23,071)
Net loss from continuing operations	\$ (26,696)	\$ (33,266)
Comprehensive loss	\$ (30,027)	\$ (35,427)
Net loss per share from continuing operations (basic & diluted)	\$ (0.04)	\$ (0.06)

### Revenues

	For the nine months ended			
	September 30, 2022	September 30, 2021	Variance to Q3-2021 (\$)	Variance to Q3-2021 (%)
Revenue from adult-use cannabis products	41,918	22,446	19,472	87%
Revenue from medical cannabis products	1,828	2,100	(272)	(13%)
Revenue from toll agreements	267	2,267	(2,000)	(88%)
Total	44,013	26,813	17,200	64%

Gross revenue recognized for YTD 2022, amounted to \$44,013, an increase of 64% compared to YTD 2021 (YTD 2021 - \$26,813). The increase is mainly due to the launch of new premium flower strains (Cherry Mints, Maple Kush and HeatWave), the launch of new pre-rolls and SprChrgd infused pre-rolls, and the Company's Highly Dutch Organic™ flower continuing to gain traction in 2022. With additional sales efforts to provide direct store support with budtender and consumer education, in addition to the new listings accepted in key markets for January 2022, the Company achieved significant increased revenues in key markets.

### Gross profit

	For the nine months ended			
	September 30, 2022	September 30, 2021	Variance to Q3-2021 (\$)	Variance to Q3-2021 (%)
Net Revenue	32,124	20,775	11,349	55%
Cost of sales	25,328	16,033	9,295	58%
Gross profit (loss) before changes in fair value of biological assets	6,796	4,742	2,054	
Gross profit (loss) % before changes in fair value of biological assets	21%	23%		
Realized fair value adjustment on sale of inventory	(14,877)	(5,626)	(9,251)	164%
Unrealized gain on changes in fair value of biological assets	21,986	7,750	14,236	184%
Gross profit	13,905	6,866	7,039	103%
Gross profit (loss) %	43%	33%		

The Company's direct gross profit was \$6,796 for YTD 2022, representing 21% gross profit margin before changes in fair value of biological assets (YTD 2021 - \$4,742 representing 23% direct gross profit) reflecting improvements in production cost efficiency including higher yields per plant and higher net revenues due to sales mix of products moving towards premium flower year over year which was offset by the inventory provisions done in Q3 2022. A provision of \$1,690 was also made in Q3 2022 for obsolescence of inventory. Normalized direct gross profit without this provision would be \$8,486, or 26%.

The Company achieved an overall gross profit for YTD 2022 of \$13,905 (YTD 2021 – gross profit of \$6,866) which has increased 103% from YTD 2021 mainly due to an increase in direct gross profit and unrealized gain on changes in fair value of biological assets reflective of the increase in cultivation activities. An inventory provision highlighted above as well as an additional provision of \$4,336 on the fair value portion of the inventory provided for above was also done in Q3 2022. Without these provisions, the overall gross profit would have been \$19,930 or 62%.

### *Sales and marketing expenses*

	For the nine months ended			
	September 30, 2022	September 30, 2021	Variance to Q3-2021 (\$)	Variance to Q3-2021 (%)
Personnel costs	1,389	1,091	298	27%
Third party marketing expenses	2,191	1,405	786	56%
Travel and promotion expenses	47	6	41	683%
Sales agency costs	1,478	120	1,358	1132%
Other marketing expenses	311	142	169	119%
	<b>5,416</b>	<b>2,764</b>	<b>2,652</b>	<b>96%</b>

Sales and marketing expenses of \$5,416 for YTD 2022 increased in comparison to expenses of \$2,764 for the same period in the prior year primarily due to increased personnel costs due to integration of Galaxie personnel following the Galaxie Acquisition, additional sales efforts undertaken to provide direct store support as well as additional third-party marketing expenses commensurate with the increased revenue achieved.

### *R&D expenses*

	For the nine months ended			
	September 30, 2022	September 30, 2021	Variance to Q3-2021 (\$)	Variance to Q3-2021 (%)
Personnel costs	333	261	72	28%
Product development	36	2	34	1700%
Travel related expenses	10	36	(26)	(72%)
Other research and development expenses	43	47	(4)	(9%)
Termination benefits		125	(125)	(100%)
	<b>422</b>	<b>471</b>	<b>(49)</b>	<b>(10%)</b>

R&D expenses of \$422 for YTD 2022 decreased by \$49 in comparison to the R&D expenses for the nine months ended September 30, 2021. The Company incurred overall higher R&D personnel costs due to the integration of Galaxie's R&D personnel which was more than offset by the absence of termination benefits in 2022.

### *G&A expenses*

	For the nine months ended			
	September 30, 2022	September 30, 2021	Variance to Q3-2022 (\$)	Variance to Q3-2021 (%)
Personnel costs	6,359	5,148	1,211	24%
Office and other administrative expenses	2,192	6,535	(4,343)	(66%)
Third party professional, consulting, legal fees	4,116	3,292	824	25%
Computer and IT expenses	342	668	(326)	(49%)
	<b>13,009</b>	<b>15,643</b>	<b>(2,634)</b>	<b>(17%)</b>

G&A expenses of \$13,009 for YTD 2022, decreased by \$2,634 in comparison to expenses of \$15,643 for the nine months ended September 30, 2021. The change consisted primarily of reductions in office and other administrative expenses and computer and IT expenses as management continues to focus on cost discipline, partially offset by an increase in personnel costs due to the Galaxie Acquisition and annual salary increases.

### *Share based compensation expenses*

The Company recognized a share based compensation expense of \$1,207 for YTD 2022, compared to \$2,516 for the nine months ended September 30, 2021. The decrease is primarily due to a reduction in the value of stock options granted in YTD 2022 as well as stock options cancelled due to forfeiture and expiry. Share based compensation was valued using the Black-Scholes valuation model and represents a non-cash expense.

### ***Depreciation and amortization***

The Company recognized depreciation and amortization expense of \$10,046 for YTD 2022, compared to \$8,543 in the nine months to September 30, 2021, due primarily to Q1 2021 depreciation being \$2,043 lower as an impairment reversal was booked at the end of Q1 2021 and the full impact was recognized only from Q2 2021.

### ***Loss from operations***

Loss from operations was \$16,195 for YTD 2022, compared to \$23,071 for the nine months ended September 30, 2021, with the improvement primarily driven by higher revenue and gross profit in the current year, partially offset by increased depreciation and amortization as explained above.

### ***Impairment loss***

During the YTD 2022, the Company recognized an impairment loss related to the held for sale HemPoland Operations of \$2,489 as well as an impairment loss on the Puslinch Facility leasehold improvements of \$6,183 (YTD 2021 – impairment related to the Quebec Facility of \$17,688, HemPoland Operations \$4,442 and an impairment reversal on the Company’s Ancaster facility assets of \$21,811).

### ***Net loss from continuing operations***

The Company’s net loss from continuing operations for YTD 2022 was \$26,696 (YTD 2021 – net loss of \$33,266) which primarily reflects the improved loss from operations, gain on the revaluation of the contingent shares from the Galaxie Acquisition of \$2,601 for YTD 2022 and a gain of \$3,187 from the sale of HemPoland, partially offset by the higher overall impairment in YTD 2022 compared to that booked in YTD 2021.

### ***Comprehensive loss***

The Company’s comprehensive loss for YTD 2022, was \$30,027 (YTD 2021 - comprehensive loss of \$35,427) and is comprised primarily of the net loss from continuing operations discussed above.

## **HEMPOLAND SALE**

On September 6, 2022, the Company completed the sale of HemPoland, its wholly owned hemp cultivation and extraction business based in Poland, for proceeds of \$6,810 which included \$1,350 in cash and a \$5,460 loan forgiveness for amounts owed to HemPoland by the Company.

The results of the disposed entity which are also included in the current results are as follows:

	<b>For the three months ended</b>		<b>For the nine months ended</b>	
	<b>September 30,</b>	<b>September 30,</b>	<b>September 30,</b>	<b>September 30,</b>
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
Revenue	\$ 305	\$ 1,298	\$ 1,926	\$ 5,028
Gross profit/(loss)	\$ (19)	\$ 652	\$ 305	\$ 2,641
Expenses	\$ 176	\$ 1,251	\$ 1,124	\$ 4,075
<b>Loss from discontinued operations</b>	\$ (195)	\$ (599)	\$ (819)	\$ (1,434)
Income Tax Recovery/(Expense)	\$ 216	\$ (4)	\$ 387	\$ 139
<b>Loss from discontinued operations, net of tax</b>	\$ 21	\$ (603)	\$ (432)	\$ (1,295)
<b>Basic and diluted loss per share</b>	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.01)



Cash flows from (used in) discontinued operation

	For the three months ended		For the nine months ended	
	September 30, 2022	September 30, 2021	September 30, 2022	September 30, 2021
Net cash provided by/(used in) operating activities	\$ 119	\$ 451	\$ (147)	\$ (1,073)
Net cash provided by/(used in) investing activities	2	29	(46)	188
Net cash provided by/(used in) financing activities	(59)	126	(410)	393
<b>Net cash (outflows) inflows for the year</b>	<b>\$ 62</b>	<b>\$ 606</b>	<b>\$ (603)</b>	<b>\$ (492)</b>

### Gain on Disposal

As a result of the disposal a gain on disposal arose as follows:

	HemPoland
Proceeds from Sale	6,810
Less: Net assets at Disposal	(5,938)
Add: Reclassification of foreign currency translation reserve applicable to HemPoland	2,315
<b>Gain on Disposal</b>	<b>3,187</b>

## FINANCIAL POSITION

The table below summarizes selected information regarding the Company's financial position for the periods presented in accordance with IFRS and on a consistent basis with the Interim Condensed Consolidated Financial Statements and related notes:

	As at September 30, 2022	As at December 31, 2021	As at December 31, 2020	As at December 31, 2019
<b>Total assets</b>	<b>\$ 168,409</b>	<b>\$ 193,999</b>	<b>\$ 211,575</b>	<b>\$ 342,181</b>
<b>Total current liabilities</b>	<b>\$ 52,105</b>	<b>\$ 29,044</b>	<b>\$ 66,377</b>	<b>\$ 53,227</b>
<b>Total non-current liabilities</b>	<b>\$ 8,086</b>	<b>\$ 28,144</b>	<b>\$ 5,394</b>	<b>\$ 21,354</b>
<b>Total shareholders' equity</b>	<b>\$ 108,218</b>	<b>\$ 136,811</b>	<b>\$ 139,804</b>	<b>\$ 267,600</b>

The following is a discussion of the significant changes to selected balances in the Company's financial position as at September 30, 2022 as compared to December 31, 2021.

### Assets

The Company's consolidated cash and cash equivalents of \$1,828 as at September 30, 2022 decreased from \$4,089 as at December 31, 2021 primarily as a result of operating activities, partially offset by proceeds received in investing and financing activities. The decrease in the Company's trade receivables to \$7,042 as at September 30, 2022 (December 31, 2021 - \$8,833) relates to timing of receipts and invoicing to provincial boards. As at September 30, 2022, the Company had \$24,670 in inventory as compared to \$20,942 as at for December 31, 2021 as a result of additional cannabis inventory build up to meet increased sales and the increase in cultivation capacity with the Quebec Facility harvests now in progress. The Company's property, plant and equipment decreased by \$15,841 to \$102,139 primarily as a result of the impairment on leasehold improvements and subsequent sale and leaseback on the Puslinch Facility, and depreciation recorded for YTD 2022.

### Liabilities

The Company's accounts payable and accrued liabilities were \$19,064 as at September 30, 2022, an increase from \$17,664 as at December 31, 2021, with the increase primarily relating to increased operating activity. Payments were primarily funded by additional funds drawn under the Revolver Loan.

The Company's loans payable increased to \$30,325 at September 30, 2022 as compared to \$20,225 as at December 31, 2021 primarily due to an increase in the drawn balance, including an additional \$4,000 provided as a term portion, and accretion on the Revolver Loan.

### Equity

The Company's shareholders' equity decreased from \$136,811 as at December 31, 2021 to \$108,218 as at September 30, 2022, primarily due to an increase in the accumulated deficit of \$27,128 related to the loss from operations for the period, partially offset by an increase in share capital of \$874 primarily due to share issuances in relation to the ATM and restricted share units.

## LIQUIDITY AND CAPITAL RESOURCES

During the nine months ended September 30, 2022, the Company generated its revenue from domestic cannabis production and sales, together with draws on the Revolver Loan to finance its operations and meet its capital requirements. The Company's objectives when managing its liquidity and capital resources are to maintain a sufficient capital base to maintain investor and creditor confidence and to sustain the future development of the business.

As at September 30, 2022, the Company maintained a negative working capital of \$5,610 (December 31, 2021 – positive \$25,716) with the change from prior year-end mainly reflecting the movement of the Revolver Loan to current liabilities from non-current, as the maturity date was within a year, being June 30, 2023. The maturity date has since been extended to March 24, 2024 as part of the Fourth Amendment, please see the "Revolver Loan Credit Facility" section above and further discussion below. The total cash position was \$3,055, including \$1,227 of restricted cash (December 31, 2021 – \$4,308 of which \$219 was restricted cash). This cash will be used primarily towards covering working capital requirements and operating costs as the Company moves towards achieving positive operating cashflow.

The Company has primarily financed its operations to date through the issuance of Common Shares, warrants, and drawdowns on certain of the Company's debt facilities. Should the Company not achieve positive operating cashflow as expected, the Company may need to increase its debt or obtain capital through various means including the issuance of equity to repay its obligations or the divestiture of other assets. The Interim Condensed Consolidated Financial Statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future if revenue plans, asset sales, debt refinancing and/or additional debt or equity financing or any combination thereof is realized. In addition, the terms of the Amended and Restated Agreement require the Company to satisfy various affirmative and negative covenants and to meet certain future financial tests. A failure to comply with these covenants, including a failure to meet the financial tests, would result in an event of default under the Revolver Loan and if not cured would allow the lender to accelerate the debt, which would materially and adversely affect the business, results of operations and financial condition of the Company.

There can be no assurance that additional funding will be available to the Company, or, if available, that such funding will be on acceptable terms. If adequate funds are not available, the Company will be required to delay or reduce the scope of any or all of its projects. Management continues to pursue other alternatives to fund the Company's operations and looks to reduce costs, such as:

- Reduction of headcount and rightsizing future operating and administrative needs;
- Minimizing the Company's reliance on third party service providers and professional fees; and
- Monetize redundant and available for sale assets.

These conditions indicate the existence of a material uncertainty that casts significant doubt about the Company's ability to continue as a going concern.

Management expects that the completion of the BZAM Transaction will result in increased assets and revenues as well as reduced relative costs. A larger asset and revenue base together with reduced relative costs for the Combined Entity and reduced debt to asset ratio is expected to increase the profitability of the Combined Entity, as well as increase the likelihood of additional funding being available to the Combined Entity.

As a result of the Company entering into the Fourth Amendment of its Revolver Loan, the Company's working capital improved, subsequent to September 30, 2022, with the current portion of loans moving to long-term and the Company having additional collateral available in order to access additional funding under the \$34 million facility under the Credit Agreement.

	For the nine months ended		
	September 30, 2022	September 30, 2021	Variance to Q3-2021 (\$)
Net cash used in operating activities	\$ (11,681)	\$ (16,874)	\$ 5,193
Net cash provided from investing activities	2,046	27,694	(25,648)
Net cash provided/(used) by financing activities	6,001	(16,601)	22,602
Net effects of foreign exchange	532	(405)	937
Decrease in cash and cash equivalents	\$ (3,102)	\$ (6,186)	\$ 3,084

### ***Operating Activities***

For the nine months ended September 30, 2022, net cash used in operating activities was \$5,193 lower than the nine months ended September 30, 2021. The improvement was achieved primarily due to increased sales and improved gross profit margins for the nine months ended September 30, 2022.

### ***Investing Activities***

For the nine months ended September 30, 2022, the net cash from investing activities was \$25,648 lower than the nine months ended September 30, 2021. The decrease was primarily due to the sale of the Quebec Facility in June 2021 as well as an increased transfer to restricted cash in Q2 2022 related to funds in the sweep account designated for repayment of the Revolver Loan partially offset by the sale of HemPoland in Q3 2022.

### ***Financing Activities***

For the nine months ended September 30, 2022, net cash provided in financing activities was \$22,602 higher than the nine months ended September 30, 2021. The increase was primarily the result of repayment of its senior secured credit facility in Q2 2021 of \$32,200, and a \$9,816 increase in funds drawn under the Revolver Loan in 2022, partially offset by a year over year decrease in cash proceeds from the issuance of Common Shares and warrants of \$9,117, and decrease in cash proceeds from the exercise of stock options and warrants of \$7,560.

### ***Contractual Obligations***

The Company had the following estimated gross contractual obligations as at September 30, 2022, which were expected to be payable in the following respective periods:

	Contractual cash flows - 12 months ending <sup>(1)</sup>							
	Carrying amount	Total	September 2023	September 2024	September 2025	September 2026	September 2027	Thereafter
	\$	\$	\$	\$	\$	\$	\$	\$
Accounts payable and accrued liabilities	19,064	19,064	19,064	-	-	-	-	-
Sales taxes payable	531	531	531	-	-	-	-	-
Loans <sup>(2)</sup>	30,325	33,869	33,869	-	-	-	-	-
Lease liabilities	9,449	22,545	1,363	1,366	1,377	1,478	1,498	15,463
Total contractual obligations	59,369	76,009	54,827	1,366	1,377	1,478	1,498	15,463

<sup>(1)</sup> Contractual cash flows include expected interest payable until the maturity date.

<sup>(2)</sup> Subsequent to September 30, 2022, the lender extended the maturity of the Revolver Loan to March 24, 2024.

The Company's accounts payable and accrued liabilities include consolidated trade payables and accrued liabilities for work incurred, including for the construction of the facilities and the payables related to its licencing revenue stream.

The contractual cash flows in the table above include the relevant interest and principal payments related to the total of \$31,117 drawn on the Revolver Loan as at September 30, 2022, payable until maturity dates. Over the balance of 2022, the Company expects further draws on the \$2,883 available credit under the Revolver Loan secured by trade receivables, for which it will have to incur interest charges based on actual use.

The Company's lease liabilities are measured in accordance with IFRS 16 where the Company has recognized an increase to both assets and liabilities on the consolidated statements of financial position, as well as a decrease to operating expenses (for the removal of rent expense for leases), an increase to depreciation and amortization (due to depreciation of the right-of-use assets), and an increase to finance costs (due to accretion of the lease liability).

### ***Other Contractual Commitments***

The lease for the office space of the Company's headquarters required the issuance of a letter of credit in the amount \$350, which may be drawn upon by the landlord in the event of a material breach of the agreement. As at September 30, 2022, there have been no breaches and no amounts have been drawn upon this letter of credit.

Pursuant to some of the agreements related to the Company's Hamilton Facility, as at September 30, 2022, the Company had letters of credit in the amount of \$129 which may be drawn upon in the event of material breaches of the respective agreements. These letters of credit bear conventional rates of interest partially offset by the interest earned on guaranteed investment certificates

("GIC") securing the letters as collateral. The Company has pledged corresponding GICs as collateral, which have been recorded in other assets. As at September 30, 2022, there have been no breaches and no amounts have been drawn on the letters of credit.

In addition, in connection with the Galaxie Acquisition, the Company acquired a 20-year lease on the land on which the Puslinch Facility is located, which commenced on December 1, 2020. On May 17, 2022 the Company also completed the Puslinch Transaction described above.

### ***Claims and Litigation***

From time to time, the Company and/or its subsidiaries may become defendants in legal actions and the Company intends to defend itself vigorously against all legal claims. The Company is subject to certain employment related claims by a former employee for which a provision in accounts payable and accrued liabilities has been recognized only to the extent that it is likely to result in future economic outflows. The Company has also been subject to a claim by former warrant holders for approximately \$1,250. The claim was settled in Q3 2022 for \$325. On August 3, 2020, the Company was named as a defendant in a litigation matter commenced in the United States District Court for the Middle District of Georgia relating to a disposed minority investment in a U.S. based beverage incubation business, seeking, among other things, unquantified compensatory damages and injunctive relief. The case was settled for US\$75 thousand. Other than the claims previously described, the Company is not aware of any other material or significant claims against the Company.

Should the remaining claim or any other litigation in which the Company becomes involved be determined against the Company, such a decision could adversely affect the Company's ability to continue operating, the value or market price for the Common Shares and could require the use of significant resources. Even if the Company is involved in litigation and is ultimately successful, litigation can require the redirection of significant resources. Litigation may also create a negative perception of the Company's brand.

### ***Use of Proceeds from Previous Financings***

The Company included a detailed disclosure of the Company's intended use and actual use of proceeds for financings in 2020 in the Company's MD&A for the 2020 year end. The Company updated this previous disclosure on its intended use of proceeds from the most recent offering with the subsequent actual use of those proceeds in its MD&A for the year ended December 31, 2021 (the "Annual MD&A"), together with an explanation of any variances and the impact of those variances, if any, on the Company's ability to achieve its current business objectives. As at the date of this MD&A, there have been no updates to the use of proceeds disclosure or additional financings since the Annual MD&A.

## **OFF-BALANCE SHEET ARRANGEMENTS**

As at the date of this MD&A, the Company had no material off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on the financial performance or financial condition of the Company.

## **CRITICAL ACCOUNTING ESTIMATES, JUDGEMENTS AND CHANGES IN ACCOUNTING POLICIES**

There were no significant changes in the Company's accounting policies and critical accounting estimates for the nine months ended September 30, 2022. The preparation of the Interim Condensed Consolidated Financial Statements requires the use of estimates and judgements that affect the application of the Company's accounting policies and reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

## **FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS**

### **[a] Fair values**

The Company's financial instruments were comprised of the following as at September 30, 2022: cash and cash equivalents; restricted cash; refundable sales tax receivable; trade receivables; other current assets; accounts payable and accrued liabilities; sales taxes payable; loans and contingent consideration.

The fair values of the financial assets and financial liabilities are determined at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The assumption for the instrument's recorded at amortized cost is that the instrument's fair value approximates their carrying amount is largely due to the short-term maturities of these instruments.

## [b] Fair value hierarchy

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value. During the nine months ended September 30, 2022, there were no transfers of amounts between levels (year ended December 31, 2021 – no changes).

## [c] Management of key risks arising from financial instruments

### *Credit Risk*

As at September 30, 2022, the Company's trade receivables had two customers whose balances were individually greater than 10% of total trade receivables as at September 30, 2022 (December 31, 2021 – two customers). Customer A accounted for 50% and Customer B accounted for 20% of trade receivables as at September 30, 2022 (December 31, 2021 – Customer A accounted for 48% and Customer B accounted for 24%). Customer A and B are provincial government entities.

## RELATED PARTY TRANSACTIONS

### *Identification of related parties*

Related parties as at September 30, 2022 have been identified as follows:

Related party	Business relationship	Measurement basis
Angus Footman	Director	Exchange amount
Olivier Dufourmantelle	Director, Senior Officer	Exchange amount
Louis Sterling	Director	Exchange amount
Jacques Dessureault	Director	Exchange amount
Caroline MacCallum	Director	Exchange amount
Chris Schnarr	Director	Exchange amount
Adam Jaffe	Director	Exchange amount
Sean Bovingdon	Director, Senior Officer	Exchange amount
Michel Gagne	Senior Officer	Exchange amount
Matthew Schmidt	Senior Officer	Exchange amount
Wyld GLX Corp.	Joint venture	Exchange amount

### *Key transactions with related parties*

There have been no material transactions with related parties and no unusual transactions outside of the normal course of business during the nine months ended September 30, 2022 (December 31, 2021 – none). No expense has been recognized in the current period or prior period for bad or doubtful debts in respect of amounts owed by related parties. No other new guarantees have been given or received by related parties during the nine months ended September 30, 2022. As at September 30, 2022, the Company had a loan from a company controlled by Angus Footman and Olivier Dufourmantelle, that was assumed as part of the Galaxie Acquisition, totalling \$400 (December 31, 2021 – \$1,300), which is subordinate to the Revolver Loan. There are no other receivable or payable balances with key management personnel and \$174 of director fees payable (December 31, 2021 – \$147 directors fee payable).

## **REGULATORY LANDSCAPE**

The results of operations and financial condition of the Company are subject to a number of regulations and are affected by a number of factors outside the control of management.

### ***Canadian Regulatory Landscape***

The production, distribution and sale of cannabis in Canada is strictly regulated. On October 17, 2018, the Cannabis Act and accompanying regulations promulgated under the Cannabis Act (the “Cannabis Regulations”), and the new industrial hemp regulations (the “IHR”, and together with the Cannabis Regulations, collectively, the “Regulations”), came into force, legalizing the production, distribution and sale of cannabis for adult recreational purposes, as well as incorporating the pre-existing medical cannabis regulatory scheme under one complete framework. Amendments legalizing the sale of edible cannabis, cannabis extracts, and cannabis topicals in the Canadian market came into force on October 17, 2019. A federally licensed entity with authorization to produce and sell any class of cannabis (except plants and seeds) must provide 60-days notice to Health Canada of its intent to sell any new cannabis retail product prior to making such product available for sale to provincially authorized purchasers or medical users.

Pursuant to the federal regulatory framework in Canada, each province and territory may adopt its own laws governing the distribution, sale and consumption of cannabis and cannabis accessories within the province or territory provided that the provincial or territorial legislation contains certain measures that mirror the public health policy goals of the federal regime. All Canadian provinces and territories have implemented mechanisms for the distribution and sale of cannabis for recreational purposes within those jurisdictions, and retail models vary between jurisdictions.

The Cannabis Act maintains separate access to cannabis for medical purposes, including providing that import and export licences and permits will only be issued in respect of cannabis for medical or scientific purposes or in respect of industrial hemp. Patients who have the authorization of their healthcare provider may register with Health Canada to have access to cannabis, either purchased directly from a federally licensed entity authorized to sell for medical purposes, or by registering to produce a limited amount of cannabis for their own medical purposes or designating someone to produce cannabis for them.

### ***Provincial Regulatory Framework for Recreational Cannabis***

While the Cannabis Act provides for regulation of the commercial production of cannabis and related matters by the federal government, the provinces and territories of Canada have authority to adopt their own laws and regulations governing the distribution, sale and consumption of cannabis and cannabis accessory products within the province or territory, permitting for example, provincial and territorial governments to set lower possession limit for individuals and higher age requirements. Currently each of the Canadian provincial and territorial jurisdictions has established a minimum age of 19, except for Alberta, where the minimum age is 18, and Québec, where the minimum age is 21.

All Canadian provinces and territories have implemented regulatory regimes for the distribution and sale of cannabis for recreational purposes within those jurisdictions. In most provinces, provincial/territorial crown corporations act as intermediaries between entities licensed federally under the Cannabis Act and consumers, such bodies acting in some jurisdictions as exclusive cannabis wholesalers and distributors, and in some instances as exclusive retailers.

Some provinces also authorize municipal governments to impose additional requirements and regulations on the sale of recreational cannabis, such as by restricting the number of recreational cannabis retail outlets that are permitted in a certain geographical area. Municipal zoning authority also generally permits a municipality to restrict the geographical locations wherein such retail outlets may be opened.

### ***Regulatory Landscape Outside Canada***

The Company only conducts business in jurisdictions outside of Canada where such operations are legally permissible in accordance with all laws of the foreign jurisdiction, the laws of Canada and the rules of the CSE. The legal and regulatory requirements in the foreign countries in which the Company operates with respect to the cultivation and sale of cannabis, as well as local business culture and practices, are different from those in Canada. Prior to commencing operations in a new country, in partnership with local legal counsel, consultants and partners, the Company conducts legal and commercial due diligence in order to ensure that the Company and its officers and directors gain a sufficient understanding of the legal, political and commercial framework and specific risks associated with operating in such jurisdiction. Where possible, the Company seeks to work with

respected and experienced local partners who can help the Company to understand and navigate the local business and operating environment, language and cultural differences. In consultation with advisors, the Company takes steps deemed appropriate in light of the level of activity and investment it expects to have in each country to ensure the management of risks and the implementation of necessary internal controls.

### ***United States***

“Marijuana” is a Schedule I controlled substance under the United States Controlled Substances Act of 1970. On December 20, 2018, hemp (defined as the plant *cannabis sativa* L. and its derivatives, extracts and cannabinoids with THC content of not more than 0.3% on a dry weight basis) was removed from Schedule 1 of the list of controlled substances under United States federal law in accordance with the United States Agriculture Improvement Act of 2018, commonly known as the “2018 Farm Bill”. The 2018 Farm Bill does not affect any other cannabis product and therefore cannabis and cannabis derivatives that do not meet the definition of hemp, and activities involving them, remain illegal under United States federal law. On October 29, 2019, the United States Department of Agriculture (the “USDA”) released an interim final rule for regulations governing hemp production in the United States which will be superseded by a final rule that was published January 19, 2021 and will become effective March 22, 2021. The Farm Bill also authorizes individual states and Indian Tribes to regulate hemp in their jurisdiction by developing and seeking USDA approval of a regulatory plan. Notwithstanding the 2018 Farm Bill, the U.S. FDA prohibits cannabis (including hemp) and its derivatives, including cannabidiol (CBD), for use as an ingredient in food and drink. The U.S. FDA held a public hearing on May 31, 2019, to obtain input from stakeholders regarding the regulation of products containing cannabis and cannabis derivatives. On March 11, 2020, the U.S. FDA extended indefinitely the comment period for that hearing. In addition, any ingredient derived from hemp in food is subject to the premarket approval requirements applicable to food additives, unless that use is “generally recognized as safe” (“GRAS”). The U.S. FDA has issued letters of no objection to at least three GRAS notices for ingredients derived from hemp seed that contain trace amounts of THC and CBD but has not to date addressed whether hemp-derived THC, CBD or other cannabinoids in non-trace levels are GRAS.

The U.S. federal budget, as currently in effect, includes the Rohrabacher-Farr Amendment, which prohibits the funding of federal prosecutions with respect to medical cannabis activities that are legal under state law. There can be no assurances that the Rohrabacher- Farr Amendment will be included in future appropriations bills or budget resolutions. At this time, there is still very little clarity as to how President Joseph Biden, or Attorney General Merrick Garland, will enforce federal law or how they will deal with states that have legalized medical or recreational marijuana. While bipartisan support is gaining traction on decriminalization and reform (for example, the Marijuana Opportunity Reinvestment and Expungement Act, which, if enacted into law, would decriminalize and regulate cannabis on a federal level in the United States, was passed by the United States House of Representatives on April 1, 2022), there is no imminent timeline on any potential legislation. There is no guarantee that the current Presidential administration, or any future administration, will not change its stated policy regarding the low-priority enforcement of U.S. federal laws that conflict with State laws. There is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed, amended or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions.

### ***Germany***

In March 2017, the German legislature introduced “The Cannabis as Medicine Act” (Gesetz zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften) which regulates the requirements for the marketability of cannabis pharmaceuticals and their inclusion in health insurance plans. Under this Act, statutory insured patients suffering from a severe disease (i.e. life-threatening or seriously affecting quality of life) are entitled to treatment with medicinal cannabis (flowers or extracts in standardized quality) if (i) generally recognized treatment in accordance with medical standards is either not available, or cannot be applied in individual cases according to the justified assessment of the treating physician, and (ii) if there is a not entirely distant prospect of a noticeable positive effect on the course of the disease or on serious symptoms.

Importers of cannabis pharmaceuticals which have not been produced in an EU/EFTA Member State and which shall be distributed in Germany on a commercial or professional basis must apply for an import authorization to the competent health authority in the federal state (Bundesland) in which the importer is based pursuant to section 72 Medicinal Products Act (Arzneimittelgesetz – “AMG”). Generally, the import authorization can be issued for cannabis from cultivations controlled by the country of origin pursuant to the requirements of the 1961 UN Single Convention on Narcotic Drugs. Additionally, importers must apply for a manufacturing authorization pursuant to section 13 AMG if they carry out at least one manufacturing step within the meaning of section 4 (14) AMG (e.g. preparing, formulating, treating or processing, filling, decanting, packaging, labelling) after import. Furthermore, the distribution of drug products treated with radiation (e.g. E-Beam) requires a permit under the German Regulation on Drug Products treated with Radiation (Verordnung über radioaktive oder mit ionisierenden Strahlen behandelte Arzneimittel – “AMRadV”).

The marketing of medicinal cannabis products that qualify as finished medicinal products requires a marketing authorization issued by the competent Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte – “BfArM”).

Pursuant to sec. 72a AMG, importers of medicinal cannabis must ensure that their products have been produced in compliance with applicable quality standards and must obtain a written confirmation from a competent authority to prove compliance. In particular, cannabis medicinal products must be manufactured in compliance with the manufacturing standards of the Pharmaceuticals and Active Agent Manufacturing Ordinance (Arzneimittel- und Wirkstoffherstellungsverordnung – “AMWHV”) which implements the EU Good Manufacturing Practice (“EU GMP”). In addition to standards for the growing and cultivation of the cannabis plant itself, such as the Good Agricultural and Collection Practice (GACP), which is annexed to the EU-GMP, specific pharmaceutical quality standards must be met before placing the product on the market. Such standards are established by pharmaceutical monographs (e.g. “Cannabis Flowers”, “Cannabis Extract”), which are published by the BfArM in the German Pharmacopoeia (Deutsches Arzneibuch – “DAB”).

Finally, medicinal cannabis products with a THC concentration of at least 0.2 percent qualify as narcotics under German law and are therefore subject to the authorization requirements under the German Narcotic Drugs Act (Betäubungsmittelgesetz – “BtMG”). Under this Act, the seller, buyer and other processors (e.g. importers, distributors, etc.) of medicinal cannabis products must obtain an authorization by the BfArM. Such an authorization has been issued per se for qualified doctors and pharmacists who sell or buy narcotics for the treatment of a patient or in the course of the operation of a pharmacy. Although CBD as such is not subject to the BtMG unless the possible THC traces exceed 0.2 percent, it is currently unclear whether products containing CBD will be classified and marketed as industrial hemp products or food rather than narcotic drugs following a judgment from the Court of Justice of the European Union on November 19, 2020 and the European Commission’s ongoing review of applications for approval of products containing CBD as novel foods. In its ruling of March 24, 2021, the German Federal Court of Justice (Bundesgerichtshof - “BGH”) ruled that the sale of hemp flowers and leaves to end-consumers may qualify as a narcotic but is not necessarily prohibited under the BtMG, provided that these products serve exclusively commercial or scientific purposes without intent to cause intoxication.

## **RISK FACTORS AND UNCERTAINTIES**

Many factors could cause the Company’s results of operations, performance and financial condition to differ materially from those expressed or implied by the forward-looking statements and forward-looking information contained in this management’s analysis and discussion, including the following factors, which are discussed in greater detail under the heading “Risk Factors” in the Company’s current Annual Information Form as updated by subsequent reports, filed with securities regulators and available on [www.sedar.com](http://www.sedar.com), which risk factors are incorporated by reference into this document and should be reviewed in detail by all readers:

- the ongoing impact of COVID-19;
- the Company’s ability to continue as a going concern;
- the Company’s ability to raise required additional capital through the sale of equity or debt instruments or the factoring of receivables or otherwise;
- the Company has a limited operating history;
- the Company may be unable to achieve revenue growth and development;
- there are factors which may prevent the Company from the realization of growth targets;
- the Company’s actual financial position and results of operations may differ materially from the expectations of the Company’s management;
- the Company may incur significant ongoing costs and obligations related to its investment in infrastructure, growth, research and development, regulatory compliance and operations;
- there is no assurance that the Company will turn a profit or generate immediate revenues;
- the Company’s management has broad discretion concerning the use of net proceeds of the ATM program;
- the Company is subject to risks typically associated with secured debt financing;
- the Company may incur additional indebtedness;
- the adult-use cannabis market in Canada is a relatively new industry;
- the adult-use cannabis market in Canada may experience supply and demand fluctuations that could result in revenue and price decreases;
- the Company’s business is dependent on key supply chains which could be adversely disrupted by a number of factors including, among others, major health issues or pandemics;
- the Company is reliant on regulatory approvals and cultivation licences for its ability to grow, process, package, store and sell cannabis and other products derived therefrom, and these regulatory approvals are subject to ongoing compliance requirements, reporting obligations and fixed terms requiring renewal;



- any failure on the Company's part to comply with applicable regulations could prevent it from being able to carry on its business and there may be additional costs associated with any such failure;
- under Canadian regulations, a Licensed Producer of cannabis is restricted regarding the type and form of marketing it can undertake which could materially impact sales performance;
- the Company's industry is experiencing rapid growth and consolidation that may cause the Company to lose key relationships and intensify competition;
- the Company may be unsuccessful in competing in the overall legal adult-use cannabis market in Canada and any other countries it intends to operate in;
- if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the cannabis market;
- the Company, or the cannabis industry more generally, may receive unfavourable publicity or become subject to negative consumer or investor perception;
- the Company's products may not have, or may not be perceived to have, the effects intended by the end user;
- if the Company is unable to develop and market new products, it may not be able to keep pace with market developments;
- there has been limited study on the health effects of cannabis products, including CBD, and future clinical research studies may lead to conclusions that dispute or conflict with the Company's understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of such products;
- consumer preferences may change and the Company may be unsuccessful in retaining customers;
- trade of cannabis for non-medicinal purposes within Canada may be restricted by the Canadian Free Trade Agreement;
- the Company must rely on international advisors and consultants in the foreign countries in which it operates and intends to operate;
- the Company is required to comply concurrently with federal, state or provincial, and local laws in each jurisdiction where it operates or to which it exports its products;
- the Company has entered into and in the future may seek to enter into strategic alliances including contractual relationships, joint ventures, selective acquisitions, licensing arrangements or other relationships, or expand the scope of currently existing relationships, with third parties that the Company believes will have a beneficial impact, and there are risks that such strategic alliances or expansions of the Company's currently existing relationships may not continue or enhance its business in the desired manner;
- the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations;
- the cultivation of cannabis includes risks inherent in an agricultural business including the risk of crop loss, sudden changes in environmental conditions, equipment failure, product recalls and others;
- the Company is reliant on key inputs, such as water and utilities, and any interruption of these services could have a material adverse effect on the Company's finances and operation results. The Company is also dependent on access to skilled labour, equipment and parts;
- the Company is vulnerable to rising energy costs;
- the Company's quality control systems may not operate effectively;
- the Company's cannabis products may be subject to recalls for a variety of reasons, which could require it to expend significant management and capital resources;
- the Company faces an inherent risk of exposure to product liability;
- the Company's operations are subject to safety, health and environmental laws and regulations applicable to its operations and industry in the various jurisdictions in which it operates, and it may be held liable for any breaches of those laws and regulations;
- the Company could be liable for fraudulent or illegal activity by its employees, contractors and consultants resulting in significant financial losses or claims against the Company;
- the Company may become subject to litigation in the ordinary course of business;
- the Company will be reliant on information technology systems and may be subject to damaging cyber-attacks;
- the Company may be exposed to liability or the threat of liability in relation to the use of customer information and other personal and confidential information;
- the Company may be subject to risks related to the protection and enforcement of its intellectual property rights, or intellectual property it licenses from others, and may become subject to allegations that it or its licensors are in violation of intellectual property rights of third parties;
- the Company may be subject to breaches of security at its facilities;
- management may not be able to successfully implement adequate internal controls over financial reporting;
- if the Company has a material weakness in its internal controls over financial reporting, investors could lose confidence in the reliability of the Company's financial statements, which could result in a decrease in the value of its securities;
- the Company has negative operating cash flow;
- the Company may be subject to credit risk;
- tax and accounting requirements may change in ways that are unforeseen to the Company and it may face difficulty or be unable to implement or comply with any such changes;

- the Company may not be able to renew or secure adequate insurance to protect its assets, operations and employees;
- fluctuations in foreign currency exchange rates could harm the Company's results of operations;
- U.S. border officials could deny entry into the U.S. to non-U.S. citizens who are employees of or investors in companies with cannabis operations in the United States and Canada;
- the price of the Common Shares in public markets may experience significant fluctuations;
- if securities or industry analysts do not continue to publish research, or publish inaccurate or unfavourable research, about the Company's business, the Common Share price and trading volume could decline;
- the Company continues to sell shares for cash to fund operations, expansion, and mergers and acquisitions that will dilute the current shareholders;
- it is not anticipated that any dividends will be paid to holders of Common Shares for the foreseeable future; and
- the Company is subject to ongoing reporting requirements under applicable securities laws and exchange policies.

In addition, the Company highlights the following risk factors:

***Potential Expansion into the US:***

A potential expansion of the business and operations of the Company into the U.S. may require significant regulatory approvals, which could involve potentially high up-front costs, and there can be no assurances that the Company would be able to obtain such approvals after paying such costs. Following an expansion into the U.S., the Company would be subject to heightened regulatory and financial scrutiny which could lead to increased costs and have a material adverse effect on the financial position of the Company. As at the date of this MD&A, all cannabis-related practices and activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. This may pose a number of potential risks to the Company, including risk associated with violation of the U.S. Controlled Substances Act, banking, financial transactions, prosecution of Company employees, and violations of anti-money laundering laws and regulations.

***Assumptions related to cash flows and future sales of the Company's product lines***

The Company expects to be required to fund negative Canadian operating cash flows prior to achieving positive Canadian operating cash flows and expects that the Company's financial resources and expected revenues and draw downs on its Revolver Loan, will be sufficient to pay its obligations and fund its operations for the coming months. Achieving positive Canadian operating cash flows and funding operations for the coming months is reliant on revenues and working capital requirements being in line with expectations, which is in turn reliant on, among other things, future sales of the Company's product lines over the coming months. The Company's expectations of positive Canadian operating cash flows and of achieving sufficient revenues to fund, when taken together with its other financial resources, its operations over the coming months is based on a variety of assumptions relating to production and production capacity, growth in the number of product offerings and store locations in which the Company's products are sold, growth in total sales, consumer demand for the Company's products, market pricing of cannabis products, cost of sales, sales and marketing expenses, the pace of opening of and increase in the total number of recreational cannabis retail stores across Canada, and the total size of the Canadian recreational and medical cannabis markets over the coming months. Actual results may vary materially from the Company's expectations if any of the Company's assumptions are inaccurate. Accordingly, readers should not place undue reliance on forward-looking statements, including the Company's expectations relating to future Canadian operating cash flows and sales of its products. The Company does not undertake to update or revise any forward-looking statements, except as, and to the extent required by, applicable securities laws in Canada. See "Cautionary Statement Regarding Forward-Looking Information". Actual results may also be impacted by all of the risk factors in this MD&A and in the Company's most recently filed Annual Information Form.

***Acquisition and Integration Risk***

The Company recently completed the Galaxie Acquisition and subsequent to the quarter end completed the BZAM Transaction. It may in the future make further acquisitions and investments that could divert management's attention, result in operating difficulties and dilution to our shareholders and otherwise disrupt our operations. The Company may have difficulty integrating any such acquisitions, including the BZAM Transaction, successfully or realizing the anticipated benefits therefrom, any of which could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and prospects.

Pursuing potential strategic acquisitions or investment opportunities is one possible growth strategy. Any transactions that the Company enter into could be material to its business, financial condition, results of operations, cash flows and prospects. The process of acquiring and integrating another company or technology could create unforeseen operating difficulties and expenditures. Acquisitions and investments involve a number of risks, including:

- diversion of management time and focus from operating the Company's business;
- use of resources that are needed in other areas of the Company's business;
- integration of the acquired company;
- implementation or remediation of controls, procedures and policies of the acquired company;
- difficulty integrating the accounting systems and operations of the acquired company;
- coordination of product, engineering and selling and marketing functions, including difficulties and additional expenses associated with supporting legacy services and products and hosting infrastructure of the acquired company and difficulty converting the customers of the acquired company onto its platform, including disparities in the revenue, licensing, support or professional services model of the acquired company;
- difficulty integrating, supporting or enhancing acquired products or services, including difficulty in transitioning acquired products or services;
- retention and integration of employees from the acquired company, and preservation of its corporate culture;
- the potential loss of key employees;
- unforeseen costs or liabilities, including the use of substantial portions of its available cash to consummate the acquisition;
- adverse effects to its existing business relationships with customers as a result of the acquisition or investment;
- the possibility of adverse tax consequences;
- litigation or other claims arising in connection with the acquired company or investment; and
- the need to integrate potential operations across different cultures and languages and to address the particular economic, currency, political and regulatory risks associated with specific countries.

Acquisitions are accompanied by the risk that the obligations and liabilities of an acquired company or asset may not be adequately reflected in the historical financial statements of or other financial information relating to such company or asset and the risk that such historical financial statements may be based on assumptions, which are incorrect or inconsistent with the Company's assumptions or approach to accounting policies. In addition, such future acquisitions could involve tangential businesses which could alter the strategy and direction of the Company. Furthermore, a significant portion of the purchase price of companies the Company has acquired may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. In the future, if the Company's acquisitions do not yield expected returns, the Company may be required to take charges to its operating results based on this impairment assessment process, which could adversely affect its results of operations.

Although the Company has conducted and will conduct due diligence in connection with potential strategic acquisitions or investment opportunities and potential vendors have, may or will provide a number of representations and warranties in favour of the Company in connection with these acquisitions, an unavoidable level of risk remains regarding any undisclosed or unknown liabilities of or issues concerning the acquired entities. Following the closing of any potential strategic acquisitions or investment opportunities, the Company may discover that it has acquired substantial undisclosed liabilities or that certain of the representations made by the vendors are untrue. There can be no assurance of recovery by the Company from potential insurers or potential vendors for any breach of the representations, warranties or covenants to be provided by such potential vendors under the applicable acquisition agreements because there can be no assurance that the amount and length of such potential insurance coverage or of the potential indemnification obligations will be sufficient to satisfy such potential obligations, or that such potential vendors will have any assets or continue to exist. The Company's eventual inability to claim for full indemnification from potential vendors could have a material and adverse effect on the Company.

Acquisitions and investments may also result in dilutive issuances of equity securities, which could adversely affect its share price, or result in the incurrence of debt with restrictive covenants that limit the Company's future uses of capital in pursuit of business opportunities. Additionally, the Company, and any potential target for a strategic acquisition or investment as a combined entity, is subject to numerous risks that could adversely affect the Company's growth and profitability, including: (i) the risk that the Company may not be able to successfully manage a potential target for a strategic acquisition or investment's operations, (ii) the risk that its operational, financial and management systems may be incompatible with, or inadequate to effectively integrate and manage systems acquired from potential target for a strategic acquisition or investment, (iii) the risk that a potential strategic acquisition or investment may require financial resources that could otherwise be used in the development of other aspects of its business, (v) the risk that the Company may not obtain the consents required under agreements entered into with third parties, (vi) the risk that the integration process may result in operational problems, costs, expenses, liabilities, including loss of contracts and customers, and (vii) the risk that the Company's key management or employees and of a potential target for a strategic acquisition or investment may not be retained or may leave following the strategic acquisition or investment, which could have a significant impact on the combined entity's operations, specifically if such departures were to occur in positions or roles which require significant technical and operational knowledge and for which qualified replacement personnel is scarce.

The successful integration of recent and potential strategic acquisitions or investments will also require cooperation between the Company's employees and the acquired companies or investees and is subject to the risk that personnel from the Company and the acquired companies or investees may not be able to work together successfully, which could adversely impact the Company's business, financial condition and results of operations. The Company may not be able to identify acquisition or

investment opportunities that meet its strategic objectives, or to the extent such opportunities are identified, the Company may not be able to negotiate terms with respect to the acquisition or investment that are acceptable to the Company.

### ***Permits and Approvals on Real Property***

The Company's operations may require permits from various federal, provincial and local governmental authorities and will be governed by laws and regulations governing cannabis, occupational health, waste disposal, land use, environmental protections, and other matters. Adverse changes or developments affecting the Company's facilities, including but not limited to the failure to maintain all requisite regulatory and ancillary permits and licenses, the failure to comply with state or municipal regulations, or a breach of security, could have a material adverse effect on the Company's business, financial condition, results of operations and prospects. In addition, any breach of any leases relating to any of the Company's real property, or any failure to renew any applicable leases on materially similar or more favourable terms, may have a material adverse effect on the Company's business, financial condition, results of operations and prospects, and could also have an impact on the Company's ability to continue operating.

The Puslinch Facility is subject to provincial and municipal regulation and oversight, including the acquisition of all required regulatory and ancillary permits to conduct operations or undertake any construction. Any breach of regulatory requirements, security measures or other facility requirements, including any failure to comply with recommendations or requirements arising from inspections by government regulators at all levels, could also have an impact on the Company's ability to keep the Puslinch Facility in good standing, and to continue operating its business. There can be no guarantee that the Company has or will be able to obtain all necessary permits and approvals.

The Puslinch Facility continues to operate with routine maintenance. The Company will bear many, if not all, of the costs of maintenance and upkeep of the Puslinch Facility, including replacement of components over time. The Company's operations and the Company's financial performance may be adversely affected if the Company is unable to keep up with maintenance requirements.

## **DISCLOSURE CONTROLS AND PROCEDURES**

The Chief Executive Officer and Chief Financial Officer (the "Certifying Officers"), in accordance with National Instrument 52-109, has certified that they have reviewed the Company's Interim Condensed Consolidated Financial Statements and this MD&A (the "Filings") and that, based on their knowledge having exercised reasonable diligence, (a) the Filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made with respect to the period covered by the Filings; and (b) the financial report together with the other financial information included in the Filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the Filings..

Since the Company's Common Shares are traded on the CSE, the Company is considered a "Venture Issuer" as defined in National Instrument 51-102 *Continuous Disclosure Obligations* and is not required to certify the design and evaluation of its disclosure controls and procedures ("DC&P") nor internal controls over financial reporting ("ICFR") and has not completed such an evaluation. The inherent limitations on the ability of the Certifying Officer to design and implement on a cost-effective basis DC&P and ICFR may result in additional risks to the quality, reliability, transparency and timeliness of annual filings and other reports provided under securities legislation.

The Certifying Officers believe that any system of controls and procedures over financial reporting and disclosure, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, they cannot provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been prevented or detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by unauthorized override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Accordingly, because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## **OUTSTANDING SHARE DATA**

As of the date of this MD&A, the Company had the following securities issued and outstanding:

Common Shares <sup>(1)</sup>	140,940,573
Warrants <sup>(2)</sup>	167,591,440
Restricted share units issued to employees	26,125
Stock options	4,507,234

### **Notes:**

(1) The Company completed the Consolidation on November 8, 2022 whereby its issued and outstanding Common Shares were consolidated on a 10:1 ratio.

(2) The Consolidation Ratio will also apply to the Warrants which are currently exercisable on the basis of one Warrant for one Common Share. Accordingly, effective as of the Consolidation date, the holders of Warrants will be entitled to receive one post-Consolidation Common Share on the exercise of ten Warrants.

Included in the above issued and outstanding Common Shares are certain Common Shares currently held in escrow, as follows: (i) 4,000,000 Common Shares, comprising a portion of the purchase price of the Galaxie Acquisition (the "Purchase Price"), issued pursuant to an indemnity escrow agreement dated November 17, 2021 (the "Indemnity Escrow Agreement"), to be released from escrow no later than December 31, 2023; (ii) 5,333,333 Common Shares, comprising a portion of the Purchase Price, issued pursuant to an escrow agreement dated November 17, 2021, under which one-sixth of these Common Shares will be released every four months; and (iii) 8,571,428 Common Shares, comprising a portion of the Purchase Price, pursuant to the Indemnity Escrow Agreement, which are contingent consideration subject to the achievement of certain milestones by December 31, 2022 and are to be released from escrow no later than January 31, 2023.

See the Company's Interim Condensed Consolidated Financial Statements for a detailed description of these securities. Each security type is convertible into one Common Share.